Yangxun F. Pan - Publications

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: July 04, 2026

HAIC Combined with Lenvatinib and Pembrolizumab for Unresectable Hepatocellular Carcinoma: A Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: February 01, 2026

Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.

Journal: International journal of surgery (London, England)

Published: October 27, 2025

Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 22, 2025

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.

Journal: The Journal of clinical investigation

Published: September 23, 2025

Proposing re-classification of bile duct cancer and intrahepatic cholangiocarcinoma: A suggested modification based on the WHO classification.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 23, 2025

Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma.

Journal: Radiology

Published: February 04, 2025

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: January 31, 2025

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Journal: Liver cancer

Published: October 12, 2024

Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.

Journal: International journal of cancer

Published: September 21, 2024

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study.

Journal: Frontiers in immunology

Published: September 11, 2024

Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study.

Journal: International journal of surgery (London, England)

Published: May 22, 2024